Here's Why Seattle Genetics Stock Jumped 25.7% in October

Here's Why Seattle Genetics Stock Jumped 25.7% in October

Source: 
Motley Fool
snippet: 

Shares of Seattle Genetics (NASDAQ: SGEN) gained over 25% last month, according to data provided by S&P Global Market Intelligence. The company reported positive results from the HER2CLIMB clinical trial evaluating a combination therapy involving tucatinib, its lead drug candidate, to treat advanced breast cancer.